Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic driver in NSCLC. There seems to be a differential...
| Published in: | JTO Clinical and Research Reports |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364320300424 |